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Abstract
Matrix metalloproteinases (MMP) are well-known biological targets implicated in tumour progression, homeostatic
regulation, innate immunity, impaired delivery of pro-apoptotic ligands, and the release and cleavage of cell-surface
receptors. Hence, the development of potent and selective inhibitors targeting these enzymes continues to be eagerly
sought. In this paper, a number of alloxan-based compounds, initially conceived to bias other therapeutically relevant
enzymes, were rationally modified and successfully repurposed to inhibit MMP-2 (also named gelatinase A) in the
nanomolar range. Importantly, the alloxan core makes its debut as zinc binding group since it ensures a stable tetrahedral
coordination of the catalytic zinc ion in concert with the three histidines of the HExxHxxGxxH metzincin signature motif,
further stabilized by a hydrogen bond with the glutamate residue belonging to the same motif. The molecular decoration of
the alloxan core with a biphenyl privileged structure allowed to sample the deep S19 specificity pocket of MMP-2 and to
relate the high affinity towards this enzyme with the chance of forming a hydrogen bond network with the backbone of
Leu116 and Asn147 and the side chains of Tyr144, Thr145 and Arg149 at the bottom of the pocket. The effect of even slight
structural changes in determining the interaction at the S19 subsite of MMP-2 as well as the nature and strength of the
binding is elucidated via molecular dynamics simulations and free energy calculations. Among the herein presented
compounds, the highest affinity (pIC50=7.06) is found for BAM, a compound exhibiting also selectivity (.20) towards MMP-
2, as compared to MMP-9, the other member of the gelatinases.
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Introduction
Matrix metalloproteinases (MMPs) are a family of zinc- and
calcium-dependent endopeptidases involved in the degradation of
the extracellular matrix (ECM) [1]. They play a key role in tissue
turnover and remodelling and their over-expression is a hallmark
of various inflammatory, malignant, and degenerative diseases
[2–4]. Such evidence has led scientists, in both academia and
industry, to make considerable efforts in the attempt to develop
new MMP inhibitors (MMPIs) to contrast dysregulation of such
important enzymes [5]. At present, several potent and orally
available broad spectrum MMPIs have been discovered. However,
the toxicity and dose-limiting efficacy emerged in clinical trials,
supposedly due to non-specific inhibition, have clearly stressed the
need for more selective compounds discriminating among different
members of the MMP family [6], [7]. In view of this, great efforts
have been addressed to selectively target MMP-2 [8], better
known as gelatinase A, that plays a central role in angiogenesis
given its catalytic action in the hydrolysis of collagen type IV, the
main component of the basement membrane, as well as of
interstitial collagens like type I [9]. Besides, the expression of
MMP-2 is related to the appearance of many different human
tumours and inflammatory diseases. Likewise other MMPs, MMP-
2 contains a common sequence motif, HExGHxxGxxH that is
characterised by three histidine residues coordinating the catalytic
zinc ion, and also shares five-stranded-b-sheets (one antiparallel
and four parallel) as well as three a-helices in the zinc-based
endopeptidase fold. Nevertheless, MMP-2 has an own typical
three-dimensional structure with a catalytic domain incorporating
three fibronectin type-II-like modules that mediate interaction
with substrates such as gelatin, laminin and collagens [10], [11].
The active site is constituted by a cavity traversing the entire
enzyme and structured in a number of specific subsites interacting
with physiological substrates and targeted by natural or synthetic
inhibitors. A relevant role to ensure a potent and selective binding
[12] is exerted by the zinc metal ion acting as an anchoring site for
many zinc-binding groups (ZBGs) [13]. Besides simple functional
groups (e.g., hydroxamic and carboxylic acids, thiols and
sulfonamides), a number of higher structured molecular fragments
were successfully examined as better selective ZBGs (e.g.,
barbiturates, hydroxypyrones and hydroxypyridones) being the
chelating action towards the zinc metal ion further reinforced by
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hydrogen-bond network and van der Waals (vdW) contacts with
the protein, resulting in a consistent gain of molecular affinity and
selectivity [14]. In this respect, a wealth of information for
identifying novel chelating scaffolds was found in a local academic
collection of about 2,000 diverse and good quality compounds
prepared by our research group over the last 25 years [15], [16],
[17]. It represents the front-line of our investigations having
already being successful for the discovery of promising anticancer
lead compounds in a three years-project CGRID funded by the
European Union [18]. Our analysis was thus directed towards
compounds having functional groups or even larger molecular
substructures acting as potential ZBGs. In this respect, our
attention was engaged by a number of reaction intermediates
contained within the library that are based on the alloxan core
originally designed for the preparation of a panel of condensed
pyridazines acting as Monoamine Oxidase-B inhibitors (i.e., 1 and
2 in Figure 1) [19]. A few alloxan derivatives were thus prepared
as investigational models to study the in vitro inhibition of
gelatinase MMP-2. As a complement, further biological assays
were lately executed on MMP-9, the other gelatinase, and on
collagenase MMP-8. Satisfactorily, valuable binding affinities and
molecular selectivity were observed. In the present work, our
attention is directed to shed light on the molecular determinants
responsible for the binding affinity towards MMP-2. To this end,
the highest (i.e., 9 in Figure 1, named BAM in the following) and
lowest (i.e., 8 in Figure 1, named BCL in the following) active
alloxan derivatives were subjected to molecular dynamics (MD)
[20] and free energy calculations [21] to explain quantitatively the
gap of observed binding energies in comparison to the unsub-
stituted derivative (i.e., 7 in Figure 1, named BAR in the following)
that was used as a reference.
Materials and Methods
Setup of the systems and docking calculations
A chemical library of about 2,000 compounds was investigated
with the aim of finding potential ZBGs. It is a private academic
repository collecting all the molecules synthesized in our research
group over the last 25 years. Such molecules have a typical drug-
like profile being their design biased towards a number of
biological targets of our interest, e.g. monoamineoxidases (MAOs),
cholinesterases, aromatases, topoisomerases, serine and cysteine
proteases, diverse G protein coupled receptors and benzodiazepine
receptor. All these structures along with a number of biological
and physicochemical properties have been stored in a local
electronic library. After retrieving chemical structures in a 2D
format, reliable molecular conformations were automatically
generated by CORINA, a 3D structure generator tool, [22] and
passed to GOLD [23] for docking simulations into the MMP-2
binding site. Initial coordinates for the protein were taken from the
first NMR model (PDB entry: 1HOV), which corresponds to the
solution structure of a catalytic domain of MMP-2 complexed with
a hydroxamic acid inhibitor (i.e., SC-74020) [24].
GOLD was set to generate 10 docking poses for each molecule.
Residues within an active radius of 12 A ˚ centredonthecatalyticZn
2+
ion were explicitly accounted in docking sampling. GOLD was
flagged for the automated determination of the coordination
geometry around the zinc metal ion. More specifically, virtual
coordination points were added at locations where GOLD was
missing a coordination site and thesecoordination points were used as
fitting points that could bind to acceptors. In order to determine the
coordination geometry, GOLD performs a permuted superimposi-
tion of coordination geometry templates onto the coordinating atoms
found in the protein. Coordination fitting points were thus generated
using the template that gave the best fit in terms of RMSD from the
target. The tetrahedral and trigonal bipyramidal coordination
geometries were manually specified to allow the docking software
to prioritize the Zn metal ion. A visual inspection of poses resulting
from alloxan-based structures disclosed conformations that matched
the structural requisites for a stable coordination with the metal as
well as a suitable orientation of the biphenyl fragment into the S19
subsite. Such evidence increased our confidence in pursuing the
molecular development of these hits. As a proof of this, the reference
compound BAR was tested resulting in an inhibitory affinity in
the low nanomolar range. In continuing work, further docking
simulations were performed setting a deeper sampling of the genetic
algorithm and increasing the number of solutions per molecule up to
50. To obtain an initial structure for the complex formed between the
catalytic domain of the MMP-2 enzyme and the alloxan derivatives,
results coming from automatic docking calculations were analysed
alongwiththevaluablestructuralinformationderivedfromPDB[25]
accounting for complexes between barbiturate ligands and MMPs.
The only difference between the alloxan and 5,5-disubstituted
barbituric acid derivatives is the presence of a 5-hydroxyl group in
the former. However, such a little structural variation makes the two
compounds strongly diverse in terms of acidity and of possible
tautomeric equilibria.
At the time of writing, three PDB structures of MMPs
complexed with barbiturate inhibitors were available [26], [27].
All of them showed preferred tautomers with the N1 atom
incorporated into the metal coordination sphere having a
tetrahedral geometry, while the enolic group established a
hydrogen bond (HB) with the charged Glu121 (numbering as in
1HOV) in the active site. As a result, the enolic form of the
barbiturate is supposed to be favoured by the protein matrix over
the tautomeric keto form (that is instead prevalent in solution) [28]
(Figure 2). With this in mind, a docking pose complying with a
high score value and a ligand conformation resembling crystallo-
graphic data was used as the initial structure for MD simulations.
MD simulations
The X-ray structure of MMP-2 (PDB code 1HOV) [24] was
retrieved and, after the removal of the inhibitor, complexed with
the three selected alloxan derivatives (i.e., BAR, BCL and BAM)
by inserting docked ligands into the protein binding site. The
protonation states of the histidine residues were adjusted according
to the hydrogen bond network, while basic amino functional
groups were protonated, aromatic amino functional groups were
left uncharged and carboxylic groups were considered to be
deprotonated. The non-bonded representation proposed by Aqvist
was employed for the calcium ions, here considered with a 2+
charge [29]. A bonded representation for the zinc ions was
constructed by placing explicit bonds between the metal and the
coordinating atoms, after separately parametrizing each of them
by Hartree-Fock calculations at the HF/6-31G* level of theory. In
particular, for the structural Zn
2+ ion (Figure 3a), the adopted
bonded representation corresponds to one in which the metal ion
is linked to the His98-Ne, His70-Ne, His75-Nd and the Asp72-O
atoms by explicit molecular mechanics bonds. The catalytic Zn
2+
ion (Figure 3b) was explicitly linked to the His120-Ne, His124-Ne,
His130-Ne atoms and the N atom of the alloxan ring.
The potential energy surface (PES) of the two Zn moieties was
analyzed by using the Gaussian package [30]. A single point
energy calculation, with geometry fixed, was first performed and
used as a reference for the subsequent geometry optimization.
Then, a further single point calculation was performed on the
obtained optimal geometry. The results were finally used to derive
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complete the parametrization of the two Zn moieties [31].
The analyzed ligands were sketched and parametrized with
GAFF atom types [32]. Each structure was immersed in a cubic
TIP3P water box that extended 18 A ˚ from the protein atoms and
neutralized by addition of Na
+ counter ions using the AMBER
Leap module [33]. This led to a simulation system of 54,630 atoms
in a box of 82.84688.37680.06 A ˚ 3. The parm03 version of the
all-atom AMBER force field was used to model the system [34].
The solvent molecules were initially relaxed by energy minimiza-
tion and subsequent 30 ps of MD. The full systems were further
minimized to remove bad contacts in the initial geometry and
heated gradually to 310 K during 600 ps of MD. The SHAKE
algorithm was employed to constrain all R–H bonds. Periodic
boundary conditions were applied in all directions. The cut-off for
non-bonded interactions was set to 12 A ˚. Particle-Mesh-Ewald
(PME) was employed to include the contributions of long-range
interactions with 64 nodes in all directions [35]. Pressure (1 atm)
and temperature (310 K) were controlled during the MD
simulations by the Langevin method [36]. NAMD [37] was used
to compute 5 ns of equilibration trajectory for each model with a
Figure 1. Biological data of alloxan-based compounds 1–9. We report the pIC50 or % of inhibition at 100 mM.
doi:10.1371/journal.pone.0025597.g001
Figure 2. Keto-enol tautomerism referred to the chemical
equilibrium between the keto and enol form established by
the alloxan-like structure as described on the left-hand and
right-hand side, respectively.
doi:10.1371/journal.pone.0025597.g002
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0.6 ps.
Free energy calculations
Thermodynamic integration (TI) computes the free energy
difference between two states A and B by coupling them via a
parameter lambda, which serves as an additional, non-spatial
coordinate. This lambda formalism allows the free energy
difference between the states to be computed as:
DG0
TI~
ð 1
0
LV l ðÞ
Ll l
dl ð1Þ
The thermodynamic cycle showed in Figure 4 allows the
comparison of results from a series of TI calculations with physical
observables.
Processes A and B represent the binding of two different ligands
to a protein, while processes C and D are transformations from
one ligand to the other while it is bound to the protein (C) or
simply solvated in water (D). Since DGC2DGD=DGA2DGB,T I
calculations can be used to compute relative binding free energies,
making them useful tools in drug design or lead optimization
applications. In equation 1, V(l) is the l-coupled potential
function that corresponds to V(A) for l=0 and V(B) for l=1. The
integration was carried out over the average of the l derivative
of the coupled potential function at given l values. Since this
integration can only rarely be performed analytically, an
integration scheme was used in which simulations at different
discrete l points were performed and the value of the integral was
numerically evaluated by interpolation. A benefit of TI calcula-
tions is that several independent MD simulations at fixed l values
can be performed independently, allowing for efficient paralleliza-
tion. Moreover, additional l points can be added at any stage to
improve accuracy.
In this work, free energy calculations were used to calculate the
relative binding free energies of the three alloxan inhibitors BAR,
BCL and BAM. Free energies were computed by using the
thermodynamic integration tools of the SANDER routine
implemented in AMBER 10.0, with modified vdW interactions
(softcore potential) to ensure smooth free energy curves [38].
Each calculation consisted in two different ligand transforma-
tions: i) molecule 1 to molecule 2 in water and ii) bound to MMP-
2. For consistency, both transformations were further broken up
into three sub-steps each: step 1 consists in the removal of the
partial charge on the atoms that would be substituted or deleted
from molecule 1 (for instance, the hydrogen atom of BAR); in step
2, atomic species are substituted with no charges, hence resulting
in the calculation of the contribution of the vdW interaction to the
free energy difference (in our case, the hydrogen atom on BAR
was deleted while simultaneously inserting the chlorine atom on
BCL or the carboxamido group on BAM). Finally (step 3), the
atomic charges on the substituted groups are switched on. This
procedure is required to avoid instabilities due to the presence of a
non-zero charge on an atom whose vdW interactions get
progressively weaker. Softcore potentials were used for all the
steps 2 in our transformations to prevent the free energy
divergence caused by the zero-point singularity. In particular,
the van der Waals interactions were modified as follows [39]:
Figure 3. Bonded representation of the coordination at the structural (a) and catalytic (b) Zn
2+ ions of MMP-2.
doi:10.1371/journal.pone.0025597.g003
Figure 4. Thermodynamic cycle. Events A and B represent the
binding of two different ligands to a protein, events C and D
indicate the conversion from one ligand to the other in the
bound and hydrated states, respectively. The free energy
differences between the processes A and C can be obtained calculating
the free energy differences between B and D.
doi:10.1371/journal.pone.0025597.g004
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This means that the Lennard-Jones interactions include the parameter
l so that there are no singularities when l approaches the value 0 or 1.
Each sub-step at a definite value of l consisted in 500 steps of
steepest descent minimization, followed by 50 ps of density
equilibration and 200 ps of NPT production MD to collect dV/
dl data. A time step of 2 fs was used together with the SHAKE
algorithm, with the same parameters as for the equilibration. As an
example, Figure 5 shows the forward transformation of BAR into
BCL. Errors were estimated as reported in ref. [39] and the total
integration error was calculated by using error propagation on the
sums, differences and interpolated values.
Chemistry
Compounds in Figure 1 were prepared via aldol condensation
of alloxan and suitable methylketones as already described [19].
Substituted biphenyl methyl ketones for BCL and BAM were
prepared via Suzuki-Miyaura microwave assisted synthesis from 4-
bromoacetophenone and corresponding arylboronic acids (see
Figure 6).
MMP Inhibition assays
Inhibitory activities were determined by a fluorimetric assay,
where a pro-fluorescing peptide was used as substrate of MMP,
and the fluorogenic activity of its cleavage product was measured
after co-incubation with test compounds.
Results and Discussion
A chemical library of about 2,000 rationally designed
compounds previously synthesized in our research group was
used as starting material for this work. It is evident that the quality
of chemical collection is increased if compounds contained within
the library have drug-like properties. However, it is difficult to
define clearly the concept of druglikeness in terms of the exact
characteristics that a molecule should have in order to be viable as
a drug. There are some general criteria that can be applied in
compound acquisition programs to filter out undesirable com-
pounds. A milestone of filtering techniques is the well known Rule-
of-five developed by Lipinski [40]. The rule is based on easy-to-
calculate properties that are designed to identify compounds that
are likely to exhibit poor intestinal absorption. In this respect,
physical properties relevant to assess druglikeness (i.e., molecular
weight, logP, number of hydrogen bond donor atoms and number
of hydrogen bond acceptor atoms) were calculated for each
compound of our library. As shown in Figure 7, the likelihood of
our library to exhibit activity in any therapeutic area was estimated
by comparing its bioactive profiles with those derived from
DrugBank [41], a freely available database containing FDA-
approved small molecule drugs, FDA-approved biotech drugs,
nutraceuticals and experimental drugs.
Our local academic collection was thus interrogated via sub-
structural similarity searches of known ZBGs. Interestingly, besides
the presence of a few canonical ZBGs (i.e., thiols or carboxylic
acids), four alloxan-based structures (i.e., derivatives of the 2,4,6-
Figure 5. Thermodynamic integration for the case BAR to BCL. The plot shows the dV/dl curves assembled from 13 lambda points.
Transformations in water are represented as well as those in the protein for the three simulation steps.
doi:10.1371/journal.pone.0025597.g005
Alloxan Inhibitors for Matrix Metalloproteinase-2
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25597trioxopyrimidines) were also fished as potential hits. The rationale
behind such selection was that some 5,5-disubstituted-2,4,6-
trioxopyrimidines were already known as MMPIs [42], [43],
[44]. Actually, alloxan-based compounds were stored as chemical
intermediates for the rational design of pyrimidopyridazine
derivatives biasing the monoamineoxidases (MAO-A and MAO-
B) enzymes as potential therapeutics for Parkinson’s disease [19].
However, our attention was engaged by the presence of the 5-OH
group and by its potential role in presumably determining both
metal coordination as well as an appropriate hydrophilic-lipophilic
balance in such hydrophobic molecules. In this respect, the
bioactive potential of alloxan-based compounds available from our
collection was challenged by docking calculations with the result
that valuable scoring and posing values towards MMP-2 enzymes
were found. These initial observations increased our confidence in
the potential role of these compounds as MMP-2 inhibitors.
Interestingly, preliminary biological experimental data awarded a
number of these selected derivatives with inhibition measures in
the high micromolar range. Such selected alloxan compounds
were thus improved through a knowledge-based molecular design.
Basically, the phenyl moiety of compounds 3 in Figure 1 was
augmented to biphenyl (i.e., BAR in Figure 1), being such a
molecular fragment a privileged structure for targeting the S19
subsite of MMPs. The need of capturing selective interactions into
the S19 subsite prompted us to consider further molecular
optimizations. In this respect, the distal aromatic ring of the
biphenyl moiety was thus further decorated at the meta and para
positions by inserting two properly selected substituents with easy
commercial and chemical access as well as different Hammett s
and Hansch p constants [45]. These compounds could be
promising in the field of MMP inhibition, considering that
compounds under clinical investigation are hydroxamic acid
derivatives with similar inhibition patterns (e.g., BB-2516, Ro
32-3555) [46], [47]. On the other hand, the alloxan ring, a ZBG
other than the hydroxamic group, makes these compounds higher
desirable as they have better drug-like properties and are
presumably less toxic in vivo. In this respect, BAR was used as
lead compound for the next substitution on the biphenyl ring. In
this work, we considered a small series of derivatives differing for
type and position of substitution. Inhibition data showed that the
meta-chloro substituted biphenyl derivative is less active than the
Figure 7. The physical property profiles of our academic collection (in black) are compared with property profiles found in
DrugBank (in white). The y-axis represents the percentage of compounds, the x-axis represents the molecular weights (MW), logP, hydrogen bond
donor (HBD) and hydrogen bond acceptors (HBA) profiles.
doi:10.1371/journal.pone.0025597.g007
Figure 6. Synopsis of the synthesis of compounds 3–9 in
Figure 1. Reagents and conditions: (i) Na2CO3, (PPh3)2PdCl2, water/
dioxane, microwave heating; (ii) alloxan monohydrate, acetic acid,
reflux.
doi:10.1371/journal.pone.0025597.g006
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selective MMP-2 inhibitor. Docking calculations assisted and
drove the design and synthesis of this series of compounds.
However, as reported in literature, established scoring functions
fail to predict binding affinity of slightly different molecules as in
the case of our series comprising compounds varying only for
mono-substitutions in the distal aromatic ring of the biphenyl
fragment. As shown in Table 1, score values obtained after
docking compounds BAR, BCL and BAM in the MMP-2 binding
site are very similar and, thus, unsuitable to interpret the difference
in term of binding affinities. In order to shed light on this
experimental observation, MD simulations were carried out and
free energy differences calculated with respect to the unsubstituted
BAR. First, conventional MD simulations showed that the ligand
stays in the binding pocket, as expected due to the bonded
representation chosen for the Zn ion. The RMSD values of the
protein and the ligand BAR remained below 0.4 nm throughout
the simulation, indicating stability of the system on this timescale
(Figure 8).
As an example, Figure 9 shows BAR in the protein after 5 ns of
simulation. The inhibitor contributed to the tetrahedral coordi-
nation of the catalytic Zn ion and was engaged in favourable
interactions with the MMP-2 active site. In particular, a hydrogen
bond occurred between the enolic hydroxyl of the inhibitor and
the charged Glu121 side chain. As expected, the biphenyl
substituent was embedded into the protein hydrophobic pocket
S19.
This structure was used as starting point for TI simulations of the
transitions described above (i.e., BAR to BCL and BAR to BAM)
and the backward transitions (i.e., BCL to BAR and BAM to BAR).
Table 2 presents the free energy differences obtained by TI, along
with the inhibition data. To assess the accuracy of our calculations,
the results were compared with experimental binding data expressed
as 50% Inhibitory Concentration (IC50)v a l u e s( F i g u r e1 ) .E x p e r i -
mental binding free energies were calculated as follows:
DGbind~kBTlnKi~kBTlnIC50zC ð3Þ
where
Ki~
IC50
1z
S ½ 
km
ð4Þ
is the Cheng-Prusoff equation to convert an IC50 value into an
inhibition constant [48]. Since the applied computational procedure
calculates only free energy differences, the value of the constant C
becomes irrelevant.
As reported in Table 2, free energy differences calculated via TI
match the trend observed in the experimental data of binding
affinity: as far as forward transitions are concerned, we might
conclude that BAR and BAM have comparable binding free
energies, while BCL corresponds to a pronounced low affinity.
The error bars on these calculations are in the range of 2 kcal/
mol. This is due to the extreme difficulty of obtaining stable values
of dV/dl for the case in which the molecule is bound to the
protein. For consistency, we checked the results by performing the
same calculations in the backward direction (i.e. BCL to BAR and
BAM to BAR). It is evident in Table 3 that our calculations were
fully consistent in water, even better than expected based on our
error estimate. However the situation is dramatically different in
presence of the protein, and, although a certain consistency might
still be found in the case of BAM, there is certainly a significant
discrepancy in the case of BCL. Increasing the time of the
simulations by a factor of 2 did not contribute significantly to
reducing the error bars, and the same calculation (in particular
step 2 for the BCL case) performed with or without the SHAKE
algorithm resulted in comparable values (data not shown). It is
indeed clear from inspection of the data in Table 3 that our
procedure is in trouble only in presence of the protein. Whether
this is due to a poor sampling of protein conformations might be
an issue for subsequent studies, but is certainly beyond the reach of
the TI method. In order to clarify the source of this discrepancy,
we decided to delve into further analysis of the equilibrium MD
trajectories.
We report in Figure 10 the histograms of the values of the
dihedral angle between the biphenyl rings for the three
compounds examined.
It is known that the dihedral angle between the biphenyl rings is
about 644u: this value was typically found in the case of BAR.I ti s
evident that the biphenyl rings of BAR were preferably rotated to
determine a bimodal distribution of the torsion angle approxi-
mately equal to 645u. In the case of BAM, the distribution is no
longer a bimodal centered on the two expected values, but rather a
flattened Gaussian centered on the value 0u. The expected values
of the dihedral angles are still visited within the time frame of our
equilibration MD trajectory, although they are not sufficiently
populated as in the case of BAR. This effect becomes dramatic
in the case of BCL, for which the distribution of the dihedral
angle becomes quite sharp and centered around 0u: hence, the
Figure 8. RMSD of the C-alpha carbon atoms of MMP-2 (PDB
code: 1HOV) for the equilibration trajectories. The protein
complex with BAR (green line), BCL (red line) and BAM (blue line) is
stable within the time frame of equilibration.
doi:10.1371/journal.pone.0025597.g008
Table 1. GOLD fitness values for top-scored docking
solutions.
ID SCORE (kJ/mol)
BAR 69.72
BCL 70.79
BAM 71.02
doi:10.1371/journal.pone.0025597.t001
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biphenyl rings into a coplanar conformation supposedly better
fitting into the S19 pocket. A visual inspection, in fact, revealed that
the chlorine atom is engaged in stable vdW interactions with
Leu116, Val117 and Tyr142 residues which are all within 5 A ˚ of
the chlorine atom in all frames within the time scale of the MD
simulations. We can conclude that a meta substitution on the
second phenyl ring causes a steric hindrance such that the chlorine
atom is blocked to remain in a hydrophobic pocket where it
establishes favourable interactions with the protein residues,
although this implies a reduced conformational freedom of
the biphenyl fragment into the S19 subsite. Diversely, a para
substitution seems to be more tolerated, since it allows larger
flexibility of the two phenyl rings although less than in BAR since
the carboxamido group is involved in HB interactions with
neighbouring residues. Specifically, it has been observed that the
N atom of the carboxamido group interacts with the backbone of
Leu116 and Asn147 and with the side chain of Thr145, while the
O atom of the carboxamido group is able to contact the side
chains of Tyr144 and Arg149 residues. Additionally, both atoms
are engaged in HB interactions with water molecules in the pocket.
The most frequent interactions are those established between the
N atom of carboxamido group and carbonylic oxygen atom of
Leu116, and between the O atom of the carboxamido group and
the side chain of Arg149. Figure 11 shows the coordinates of the
atoms involved in such interactions sampled over the whole
trajectory. The HB with the Leu116 main chain is stable within
the time scale of the MD simulation, while that with the Arg149
swings among the three N atoms of its side chain.
How the reported differences contributed to the accuracy of our
free energy calculations can therefore be ascribed to the choice of the
initial conformation and sampling issues. The initial conformation in
t h ec a s eo fBAR, was slightly tilted and the distribution of the angles
became closetothat of BAMand BCL for highlvalues,asexpected.
It is then evident that both compounds will tend, within the time
frame of the calculation, to align the biphenyl rings. The calculation
in the forward direction is therefore quite reliable, while we suspect
that the one in the backward direction is affected by a poor sampling
o ft h ed i s t r i b u t i o no ft h ea n g l eb e t w e e nt h eb i p h e n y lr i n g si nBAR.I n
thisrespect, we would conclude that thebackward calculation, at least
i nt h ec a s eo fBCL, should be completely disregarded, although it
certainly represents an interesting case for subsequent more detailed
calculations.In particular, in case of calculations involving a choiceof
reaction coordinates (or collective variables), our study points out the
need to insert the angle between the biphenyl rings into the list of the
variables to be taken into account.
In conclusion, the present study has shown that the alloxan core
represents a novel ZBG ensuring a stable coordination to the catalytic
zinc ion. Such a scaffold was actually employed as chemical
intermediate for the preparation of pyrimidopyridazine compounds
acting as inhibitors of MAO-B and MAO-A enzymes for the treatment
of Parkinson’s disease [19]. The alloxan core was selected via
substructure search from our academic library containing a drug-like
collection of molecular types designed to bias several therapeutically
relevant enzymes. The bioactive potential of the alloxan core was thus
successfully enlarged to the MMP-2, a class of enzymes also known as
gelatinases that have a definite role in the breakdown of the
extracellular matrix and in the turnover of collagen, a fundamental
component of the basement membrane. The initial activities observed
towards MMP-2 were significantly increased in the nanomolar range
by the insertion of a biphenyl fragment, a privileged structure engaging
the S19 subsite. A value of pIC50 equal to 6.74 was found for BAR
Figure 9. BAR interactions with the protein binding site. The BAR molecule (in white) contributes to the tetrahedral coordination of the
catalytic Zn ion and establishes favourable interactions with the MMP-2 active site. Notice the hydrogen bond between the enolic hydroxyl of BAR
and the charged Glu121 side chain. The biphenyl substituent is embedded into the protein hydrophobic pocket S19.
doi:10.1371/journal.pone.0025597.g009
Table 2. Calculated DDG values of the forward and backward
transitions of BAR-BCL and BAR-BAM.
Transition DDGcalc (forward) DDGcalc (backward) DDGexp
BAR-BCL 13.5162.56 1.3361.96 3.45
BAR-BAM 1.1262.37 0.5762.30 20.446
Experimental DDG values are also reported for comparison.
doi:10.1371/journal.pone.0025597.t002
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us to rationally decorate the biphenyl ring. In this respect, the para
position was functionalized with the carboxamido group to obtain
BAM, the highest active compound with a pIC50 equal to 7.06. On the
other hand, BCL was instead the derivative having a chlorine atom at
the meta position of the biphenyl which determined a drop of activity
with pIC50 being as low as 4.22. We have carried out MD and free
energy calculations to investigate the binding of BAR, BCL and BAM
Table 3. Calculated DDG values for the single steps considered in the forward and backward transitions of BAR-BCL and BAR-
BAM.
Hydration step1 err1 step2 err2 step3 err3 Total Err
BAR-BAM 26.24 0.41 3.69 1.24 244.90 1.14 247.45 1.74
BAM-BAR 45.40 1.15 23.78 1.18 6.28 0.41 47.90 1.70
BAR-BCL 25.99 0.41 6.76 0.91 23.28 0.24 22.51 1.03
BCL-BAR 3.29 0.25 26.60 1.51 5.95 0.41 2.64 1.59
Complex step1 err1 step2 err2 step3 err3 Total Err
BAR-BAM 26.24 0.33 1.43 1.23 241.52 0.99 246.33 1.61
BAM-BAR 42.48 0.91 20.36 1.21 6.35 0.31 48.47 1.55
BAR-BCL 25.45 0.27 19.79 2.32 23.34 0.18 11.00 2.34
BCL-BAR 3.92 0.20 26.70 1.08 6.75 0.29 3.98 1.14
Complex-water step1 err1 step2 err2 step3 err3 Total Err
BAR-BAM 0.00 0.53 22.26 1.74 3.38 1.51 1.12 2.37
BAM-BAR 22.92 1.47 3.42 1.69 0.08 0.51 0.57 2.30
BAR-BCL 0.54 0.49 13.03 2.49 20.06 0.30 13.51 2.56
BCL-BAR 0.63 0.32 20.10 1.86 0.80 0.50 1.33 1.95
doi:10.1371/journal.pone.0025597.t003
Figure 10. Histograms of the dihedral angles between the biphenyl rings. Distributions were obtained within 5 ns of equilibration MD
trajectories. While the distribution for BAR is a symmetric bimodal centered on the expected values of 645u, the one corresponding to BAM and
BCL are peaked around the value 0u, hence pointing at a preferred planar conformation imposed by interaction with the binding pocket.
doi:10.1371/journal.pone.0025597.g010
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occurrence of a hydrogen bonding network established between the
carboxamido group buried into the deeper area of S19 subsite with a
number of polar residues of MMP-2. Although unable to dive into such
polar zone, BAR is still able to fit the S19 subsite with the result of
preserving its activity. The weaker activity of BCL can be instead
explained observing the diverse orientation of the biphenyl ring that is
forced in a coplanar conformation due to the chlorine atom trapped in
hydrophobic contacts with some hydrophobic residues. Notably, the
alloxan-based compounds demonstrated activity towards the other
gelatinase MMP-9 and in particular a good selectivity was observed for
BAM being more than 20 fold selective towards MMP-2.
The basic idea behind our current investigation was the
development of easy-to-prepare druglike molecules holding a
stable tetrahedral coordination to the catalytic zinc ion while
properly fit the S19 specificity pocket of MMP-2. In this respect, we
have explored the potential of alloxan derivatives and obtained the
molecular rationale accounting for their different affinities.
However, the design of novel MMP-2 inhibitors is still a
fascinating challenge: for instance, an even more promising route
in the direction of an enhanced molecular selectivity would target
substrate binding exosites outside the active site. The computa-
tional strategy employed in this work might well represent a
standard protocol in a further search for MMP-2 inhibitors.
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